Oncotelic Therapeutics Inc. (OTCQB: OTLC) Advancing Proprietary Solutions Focused on Nanotechnology-Enabled Drug Delivery, AI-Enhanced Biomedical Infrastructure

Tue, 02 Jun 2026 08:30:00 EST

NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- via BioMedWire -

Sapu Nano Unveils Progress in Deciparticle™ Nanomedicine Platform and AI-Driven Oncology Development at BIO 2026

Thu, 28 May 2026 08:30:00 EST

SAN DIEGO, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- via IBN -- Sapu Nano and Oncotelic Therapeutics, Inc. ("Oncotelic" or the "Company") today announced that Vuong Trieu, Chief Executive Officer, will present the Company's Deciparticle™ nanomedicine platform at the BIO International Convention 2026 in San Diego, California.

The presentation will...

Oncotelic Therapeutics Files First Quarter 2026 Financial Results and Strategic Progress

Fri, 15 May 2026 09:00:00 EST

Agoura Hills, Calif., May 15, 2026 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC) ("Oncotelic" or the "Company"), a clinical-stage biotechnology company focused on oncology, AI-enabled drug development, and advanced drug delivery platforms, yesterday filed financial results for the quarter ended March 31, 2026 through its...

Oncotelic Therapeutics Inc. (OTCQB: OTLC) Responds to BBB Challenge with Next-Gen Drug-Delivery Platform

Thu, 14 May 2026 08:30:00 EST

NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- via BioMedWire --

Sapu Nano Announces First Patient Dosed in Phase 1b Trial of Sapu003, an Intravenous Deciparticle™ Formulation of Everolimus

Wed, 13 May 2026 10:00:00 EST

First-in-human study evaluates weekly IV Sapu003 in advanced mTOR-sensitive solid tumors, including HR+/HER2- breast cancer, RCC, NETs, TSC-associated tumors, and HCC

SAN DIEGO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- via IBN -- Sapu Nano and Oncotelic (OTCQB: OTLC) today announced that the first patient has been dosed in...

Oncotelic Therapeutics Inc. (OTCQB: OTLC) Proprietary N2B System May Offer Key to Unlocking Next-Gen Therapies

Tue, 12 May 2026 08:30:00 EST

NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- via BioMedWire --

Oncotelic Therapeutics Announces Closing of a Strategic Monetization of Its CNS/Nasal Assets with Lunai Bioworks, Advancing Joint Development in Biodefense and Alzheimer's Disease

Wed, 06 May 2026 08:30:00 EST

AGOURA HILLS, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- via IBN -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC) ("Oncotelic" or the "Company"), a late-stage clinical biopharmaceutical company focused on oncology and rare diseases, today announced the consummation of a strategic asset transfer agreement with Lunai Bioworks, Inc. ("LNAI") for its N2B (nose-to-brain)...

Oncotelic Therapeutics Advances Toward Commercial Launch of AI-Enabled Robotics Platform Following Integration of 28 Million Scientific Abstracts

Thu, 30 Apr 2026 08:30:00 EST

LOS ANGELES, April 30, 2026 (GLOBE NEWSWIRE) -- via IBN -- Oncotelic Therapeutics, Inc. ("Oncotelic" or the "Company") (OTCQB: OTLC), a clinical-stage biotechnology company focused on oncology and AI-driven solutions, today provided an update on the continued advancement of its proprietary AI platform and robotics integration as it approaches initial commercial...

Oncotelic Therapeutics Provides Corporate Update on Partnership Strategy

Fri, 24 Apr 2026 08:00:00 EST

AGOURA HILLS, Calif., April 24, 2026 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. ("Oncotelic" or the "Company"), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today provided a corporate update on its partnership-driven strategy to advance its pipeline and enhance shareholder value.

Oncotelic Therapeutics Inc. (OTCQB: OTLC) Real-World Example of Scientific Advancement Influence on Evaluation

Thu, 23 Apr 2026 08:30:00 EST

NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- via BioMedWire -- Oncotelic Therapeutics Inc. (OTCQB:...

Oncotelic Therapeutics Inc. (OTCQB: OTLC) Leveraging Expertise amid Evaluation Evolution

Tue, 21 Apr 2026 08:30:00 EST

NEW YORK, April 21, 2026 (GLOBE NEWSWIRE) -- via BioMedWire -

Oncotelic Therapeutics Reports FY 2025 Results Highlighting $249M Net Income and JV Pipeline Progress

Thu, 16 Apr 2026 08:30:00 EST

AGOURA HILLS, Calif., April 16, 2026 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB:OTLC) ("Oncotelic", the "Company" or "We"), a clinical-stage biopharmaceutical company developing drugs for the treatment of orphan oncology indications, as well as antisense and small molecule injectable drugs for the treatment of cancer, today announced its financial...

Oncotelic Therapeutics Inc. (OTCQB: OTLC) Strengthening Position with AI-Driven Tech in Automated Compliance Space

Fri, 10 Apr 2026 08:30:00 EST

NEW YORK, April 10, 2026 (GLOBE NEWSWIRE) -- via AINewsWire - Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement in an editorial published by

Oncotelic Therapeutics Announces Strategic Partnership with TechForce Robotics to Commercialize PDAOAI-Enhanced GMP Robotics Platform

Thu, 02 Apr 2026 08:30:00 EST

LOS ANGELES, April 02, 2026 (GLOBE NEWSWIRE) -- via IBN -- Oncotelic Therapeutics, Inc. ("Oncotelic" or the "Company"), a clinical-stage biotechnology company focused on oncology and AI-driven solutions, today announced that it has entered into a strategic partnership with TechForce Robotics, Inc. ("TechForce") to advance the commercialization of its...

Sapu Nano to Launch Deciparticle™ Platform and Present Clinical Pipeline at BIO-Europe Spring 2026

Tue, 24 Mar 2026 08:00:00 EST

AGOURA HILLS, Calif., March 24, 2026 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB:OTLC) ("Oncotelic", the "Company" or "We" or "Our"), a leader in RNA-based therapeutics, announced today that its subsidiary Sapu Nano will formally introduce its Deciparticle^™ nanomedicine platform and present its advancing clinical...

Sapu Nano to Present Everolimus Toxicology Data at SOT 2026 Annual Meeting

Mon, 23 Mar 2026 08:00:00 EST

AGOURA HILLS, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB:OTLC) ("Oncotelic", the "Company" or "We" or "Our"), a leader in RNA-based therapeutics, announced today that its subsidiary Sapu Nano will present new data on everolimus toxicology, focusing on tissue concentration-driven effects, at the upcoming...

Oncotelic Therapeutics Inc. (OTCQB: OTLC) Announces Expanded IP Coverage, Strengthening Position in Biotech Evolution

Fri, 20 Feb 2026 08:30:00 EST

NEW YORK, Feb. 20, 2026 (GLOBE NEWSWIRE) -- via BioMedWire - Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement in an editorial published by

Oncotelic Therapeutics Inc. (OTCQB: OTLC) Key IP Portfolio Advancements Align with Biotech Asset Trend

Wed, 18 Feb 2026 08:30:00 EST

NEW YORK, Feb. 18, 2026 (GLOBE NEWSWIRE) -- via BioMedWire -- Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement in an editorial published by

Oncotelic Therapeutics, Inc. and Sapu Bioscience Expand International IP Coverage for OT-101, Strengthening CNS and Neurology Commercialization Pathway

Thu, 12 Feb 2026 08:30:00 EST

LOS ANGELES, Feb. 12, 2026 (GLOBE NEWSWIRE) -- via IBN -- Oncotelic Therapeutics, Inc. ("Oncotelic" or the "Company") and Sapu Bioscience today announced key advancements in its global intellectual property portfolio supporting OT-101, its proprietary TGF-β antisense therapeutic platform, strengthening protection across neurology, oncology, and central...

Oncotelic Therapeutics, Inc. Showcases Multi-Year Execution and Validation, Enters 2026 with Late-Stage Momentum Across Diversified Pipeline

Tue, 10 Feb 2026 08:30:00 EST

AGOURA HILLS, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- via IBN - Oncotelic Therapeutics, Inc. (OTCQB: OTLC) ("Oncotelic" or the "Company"), a clinical-stage biopharmaceutical company focused on oncology, immunotherapy, and CNS-related diseases, today provided an update on key development progress achieved during 2025 and outlined its strategic direction...

Oncotelic Therapeutics Details PDAOAI Platform and Opens Access to Its Total TGF-β Knowledge Corpus

Mon, 22 Dec 2025 08:00:00 EST

AGOURA HILLS, Calif., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB:OTLC) ("Oncotelic", the "Company" or "We" or "Our"), a leader in RNA-based therapeutics, announced today opened access to PDAOAI, its proprietary evidence-interrogation platform designed to extract biologically meaningful signals from large, complex...

Oncotelic Therapeutics and Brush and Key Foundation Announce Publication in International Journal of Molecular Sciences Highlighting Context-Dependent Biomarkers in Liver and Pancreatic Cancer

Mon, 15 Dec 2025 10:00:00 EST

AGOURA HILLS, Calif., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC) in collaboration with the Brush and Key Foundation, today announced the publication of a peer-reviewed research article in the International Journal of Molecular Sciences titled "Comparative Tumor Microenvironment Analysis for HCC...

Oncotelic and Sapu Nano Announce DeciparticleTM Led Biomarker Framework Identifying Tumors Most Likely to Respond to IV Sapu003, an Intravenous Everolimus Nanomedicine

Thu, 04 Dec 2025 10:00:00 EST

AGOURA HILLS, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC) 45% owned Joint Venture, Sapu Nano today announced new biomarker data identifying a molecular signature that predicts sensitivity to Sapu003, the company's intravenous Deciparticle™ formulation of everolimus. These data will be...

Oncotelic and Sapu Nano Announces New PK Data Demonstrating IV Sapu003 Reduces GI Accumulation of Everolimus up to 67-Fold Compared With Oral Dosing

Wed, 03 Dec 2025 09:00:00 EST

AGOURA HILLS, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC) 45% owned Joint Venture, Sapu Nano today announced new pharmacokinetic (PK) and tissue-distribution results demonstrating that Sapu003, the company's intravenous (IV) Deciparticle^™ formulation of everolimus,...

Oncotelic and Sapu Nano Unveils Broad-Applicability Deciparticle™ Nanomedicine Platform Capable of Formulating Multiple Hydrophobic Peptide, Macrolide, and Polyketide Drugs

Tue, 02 Dec 2025 08:00:00 EST

AGOURA HILLS, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC) 45% owned Joint Venture, Sapu Nano, a clinical-stage nanomedicine company, today announced new data demonstrating that its proprietary Deciparticle^™ platform enables broad and consistent formulation of...

Oncotelic Therapeutics Inc. (OTCQB: OTLC) Anticipates Major Fair-Value Uptick Following New Independent JV Valuation

Tue, 25 Nov 2025 08:30:00 EST

NEW YORK, Nov. 25, 2025 (GLOBE NEWSWIRE) -- via BioMedWire - Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement in an editorial published by

Oncotelic Therapeutics Inc. (OTCQB: OTLC) Emerging as Leader with New Independent JV Valuation

Fri, 21 Nov 2025 08:30:00 EST

NEW YORK, Nov. 21, 2025 (GLOBE NEWSWIRE) -- via BioMedWire -- Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement in an editorial published by

Oncotelic Achieves Breakthrough $1.7 Billion Pipeline Valuation Through GMP Bio Joint Venture

Thu, 20 Nov 2025 07:55:00 EST

Independent valuation reflects major advancement of OT-101 and Deciparticle™ nanomedicine platform
SAN DIEGO, Nov. 20, 2025 (GLOBE NEWSWIRE) -- via IBN -- Oncotelic Therapeutics, Inc. (OTLC) today announces that its joint venture partner, GMP Bio, has completed an independent third-party valuation of its drug...

Oncotelic Therapeutics and Sapu Bioscience Announce Publication on Sub-15 nm Nanoparticles in International Journal of Molecular Sciences

Tue, 11 Nov 2025 08:00:00 EST

Breakthrough Review Defines the Next Frontier in Precision Nanomedicine

Agoura Hills, CA, and San Diego, CA, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics Inc. (OTLC) and JV partner Sapu Bioscience today announced the publication of their landmark review article, "Sub-15 nm...

Oncotelic Therapeutics Inc. (OTCQB: OTLC) at Forefront of Effort to Optimize Next-Generation Cancer Therapies

Thu, 30 Oct 2025 08:30:00 EST

NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- via InvestorWire - Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement in an editorial published by

Sapu Nano to present at the 2025 San Antonio Breast Cancer Symposium (SABCS) Highlighting Sapu003 (Deciparticle™ Everolimus)

Thu, 30 Oct 2025 06:00:00 EST

AGOURA HILLS, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC), a biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat cancer patients by leveraging its novel PDAOAI platform and deep knowledge in nanomedicines and the tumor microenvironment, announced today...

Oncotelic Therapeutics Inc. (OTCQB: OTLC) Working to Transform Underperforming Compounds into Next-Gen Cancer Therapies

Tue, 28 Oct 2025 08:30:00 EST

NEW YORK, Oct. 28, 2025 (GLOBE NEWSWIRE) -- via InvestorWire - Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement in an editorial published by

Oncotelic to present at the 2025 San Antonio Breast Cancer Symposium (SABCS) Highlighting Sapu003 (Deciparticle™ Everolimus)

Thu, 23 Oct 2025 08:00:00 EST

Accepted Presentations Showcase First-in-Human Development, Manufacturing Innovation, and Predictive Biomarkers for Deciparticle™ Everolimus (Sapu003)

AGOURA HILLS, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC), a biopharmaceutical company founded to discover,...

Oncotelic to Present at the LD Micro Main Event XIX

Mon, 20 Oct 2025 08:00:00 EST

AGOURA HILLS, Calif., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC), a biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat cancer patients by leveraging its novel PDAOAI platform and deep knowledge in nanomedicines and the tumor microenvironment, announced today...

Sapu Nano Unveils First-in-Human Clinical Trial of Sapu-003 at 8th Australian Translational Breast Cancer Research Symposium

Wed, 08 Oct 2025 08:30:00 EST

Using Sapu Nano's proprietary Deciparticle™ technology, Sapu-003 delivers everolimus intravenously
SYDNEY, Australia, Oct. 08, 2025 (GLOBE NEWSWIRE) -- via IBN - Sapu Nano today announced the presentation of its poster, "Sapu-003: Novel Intravenous Deciparticle™ Everolimus Entering Phase 1 Study in...

Sapu Nano's Sapu003 Advances to Human Clinical Testing - Transforming Everolimus Delivery with Full Bioavailability for Breast Cancer Patients

Wed, 24 Sep 2025 08:30:00 EST

Sapu003 Designed to Overcome Limitations of Afinitor®, FDA-Approved Oral Everolimus, by Delivering Full Strength of the Drug via Intravenous Injection
SAN DIEGO, Sept. 24, 2025 (GLOBE NEWSWIRE) -- via IBN -- Sapu Nano, developer of Deciparticle™, today announced that it has received approval from Australia's...

Oncotelic Therapeutics Inc. (OTCQB: OTLC) Creating Pioneering Pipeline Designed to Transform Cancer, Rare Diseases Treatments

Thu, 18 Sep 2025 08:30:00 EST

NEW YORK, Sept. 18, 2025 (GLOBE NEWSWIRE) -- via InvestorWire - Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement in an editorial published by

Oncotelic Therapeutics Inc. (OTCQB: OTLC) Building Breakthrough Portfolio Aimed at Transforming Cancer, Rare Disease Treatments

Tue, 16 Sep 2025 08:30:00 EST

NEW YORK, Sept. 16, 2025 (GLOBE NEWSWIRE) -- via InvestorWire - Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement in an editorial published by

Oncotelic Therapeutics Highlights 2 Years of Clinical and Regulatory Advancements Across Late-Stage Pipeline

Fri, 12 Sep 2025 11:51:00 EST

AGOURA HILLS, Calif., Sept. 12, 2025 (GLOBE NEWSWIRE) -- via IBN -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC) ("OTLC" or the "Company"), a clinical-stage biopharmaceutical company developing transformative oncology and immunotherapy treatments, today announces a summary of its major accomplishments over the past two years. These milestones underscore...

Dr. Vuong Trieu, Developer of Novel Oncology and Immunotherapy Assets, Leads Oncotelic Therapeutics' Commitment to Innovation, Life-Saving Therapies

Thu, 04 Sep 2025 08:30:00 EST

Dr. Trieu's prolific career includes multibillion-dollar drug discoveries targeting cancers of the breast, pancreas and non-small cell lung cancer, among others

Oncotelic's robust portfolio and clinical pipeline is supported by the innovations and intellectual property generated by Dr....

Oncotelic Therapeutics Showcases Robust Pipeline and Founder's Broad Intellectual Property Contributions to Biopharma Industry

Thu, 28 Aug 2025 09:00:00 EST

Highlighting multibillion-dollar drug discoveries and advancing novel oncology and immunotherapy assets

AGOURA HILLS, Calif., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC) ("OTLC" or the "Company"), a clinical stage biopharmaceutical company developing transformative...

Oncotelic Therapeutics Highlights Peer Reviewed Publication Linking TGFB2 to Survival in Younger Pancreatic Cancer Patients

Thu, 17 Jul 2025 11:08:00 EST

Data support further evaluation of investigational antisense OT 101 (trabedersen) as a TGFB2 targeted approach in pancreatic ductal adenocarcinoma (PDAC).

AGOURA HILLS, Calif., July 17, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC) ("Oncotelic" or the "Company"), a clinical...

Oncotelic Therapeutics Announces Publication of Landmark Study on TGFB2 Gene Methylation as a Positive Prognostic Marker in Pancreatic Cancer

Wed, 25 Jun 2025 07:30:00 EST

AGOURA HILLS, Calif., June 25, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC) ("Oncotelic" or the "Company"), a clinical-stage biopharmaceutical company focused on RNA-based therapeutics, today announced the publication of a peer-reviewed research article highlighting TGFB2 gene methylation as a positive...

Oncotelic CEO Vuong Trieu to Present Innovative "Deciparticles" Platform at IDDST-Europe 2025 Conference in Stockholm

Tue, 22 Apr 2025 10:00:00 EST

AGOURA HILLS, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB:OTLC), a biotechnology company focused on nanomedicine and RNA-based therapeutics, announced today that its Chairman and CEO, Dr. Vuong Trieu, will deliver a keynote presentation at the 21st Annual Congress of International Drug Discovery Science &...

Oncotelic Therapeutics Reports FY 2024 Highlights and FY 2024 Earnings Compared to FY 2023

Wed, 16 Apr 2025 09:15:00 EST

AGOURA HILLS, Calif., April 16, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We"), a developer of treatments for rare and orphan indications, including Parkinson's Disease, pancreatic ductal adenocarcinoma ("PDAC"), diffuse intrinsic pontine glioma ("DIPG"), and various other cancers, today...

Oncotelic Therapeutics Publishes New Research Demonstrating Positive Prognostic Impact of Methylated TGFB2 and MGMT in Adult Glioblastoma Patients, Introduces Interactive PDAOAI

Mon, 31 Mar 2025 08:15:00 EST

AGOURA HILLS, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB:OTLC) ("Oncotelic," the "Company," or "We"), a leader in RNA-based therapeutics, today announced the publication of its latest research paper, titled, "Positive Prognostic Overall Survival Impacts of Methylated TGFB2 and MGMT in Adult Glioblastoma...

Oncotelic Therapeutics Announces Successful Completion of Phase 1 Trial of OT-101 and IL-2, Highlights Findings at SWCR 2025 Conference

Tue, 25 Mar 2025 09:00:00 EST

AGOURA HILLS, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We" or "Our"), "), a leader in RNA-based therapeutics, announced today the successful completion of a Phase 1 clinical trial evaluating OT-101, in combination with IL-2 for advanced or metastatic solid tumors. These...

Oncotelic Accesses Rapid IND Development Platform through Partnership with Medicilon

Tue, 25 Feb 2025 08:00:00 EST

AGOURA HILLS, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB:OTLC). Oncotelic Therapeutics Inc., a leader in RNA-based therapeutics, including its subsidiaries ("Oncotelic") and including Sapu Bioscience, LLC ("SAPU"), a wholly owned subsidiary of GMP Biotechnology Limited in which Oncotelic is a 45% owner, is...

Oncotelic CEO Vuong Trieu to Present Groundbreaking Research on Transforming Growth Factor Beta 2 (TGFB2) at SWCR 2025 Conference

Thu, 13 Feb 2025 08:00:00 EST

AGOURA HILLS, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC). Oncotelic Therapeutics, a leader in RNA-based therapeutics, is pleased to announce that Vuong Trieu, Ph.D., Chairman & CEO, will be delivering a featured presentation at the SWCR 2025 Conference on March 24th. His talk will highlight the central...

Oncotelic News powered by B2i Technologies - SmartWire

Sapu Nano Expands International Development of Sapu003 and Appoints Global Clinical Trials (GCT) as Lead CRO for Phase 1b Program

Oncotelic Therapeutics Inc. (OTCQB: OTLC) Advancing Proprietary Solutions Focused on Nanotechnology-Enabled Drug Delivery, AI-Enhanced Biomedical Infrastructure

Sapu Nano Unveils Progress in Deciparticle™ Nanomedicine Platform and AI-Driven Oncology Development at BIO 2026

Oncotelic Therapeutics Files First Quarter 2026 Financial Results and Strategic Progress

Oncotelic Therapeutics Inc. (OTCQB: OTLC) Responds to BBB Challenge with Next-Gen Drug-Delivery Platform

Sapu Nano Announces First Patient Dosed in Phase 1b Trial of Sapu003, an Intravenous Deciparticle™ Formulation of Everolimus

Oncotelic Therapeutics Inc. (OTCQB: OTLC) Proprietary N2B System May Offer Key to Unlocking Next-Gen Therapies

Oncotelic Therapeutics Announces Closing of a Strategic Monetization of Its CNS/Nasal Assets with Lunai Bioworks, Advancing Joint Development in Biodefense and Alzheimer's Disease

Oncotelic Therapeutics Advances Toward Commercial Launch of AI-Enabled Robotics Platform Following Integration of 28 Million Scientific Abstracts

Oncotelic Therapeutics Provides Corporate Update on Partnership Strategy

Oncotelic Therapeutics Inc. (OTCQB: OTLC) Real-World Example of Scientific Advancement Influence on Evaluation

Oncotelic Therapeutics Inc. (OTCQB: OTLC) Leveraging Expertise amid Evaluation Evolution

Oncotelic Therapeutics Reports FY 2025 Results Highlighting $249M Net Income and JV Pipeline Progress

Oncotelic Therapeutics Inc. (OTCQB: OTLC) Strengthening Position with AI-Driven Tech in Automated Compliance Space

Oncotelic Therapeutics Announces Strategic Partnership with TechForce Robotics to Commercialize PDAOAI-Enhanced GMP Robotics Platform

Sapu Nano to Launch Deciparticle™ Platform and Present Clinical Pipeline at BIO-Europe Spring 2026

Sapu Nano to Present Everolimus Toxicology Data at SOT 2026 Annual Meeting

Oncotelic Therapeutics Inc. (OTCQB: OTLC) Announces Expanded IP Coverage, Strengthening Position in Biotech Evolution

Oncotelic Therapeutics Inc. (OTCQB: OTLC) Key IP Portfolio Advancements Align with Biotech Asset Trend

Oncotelic Therapeutics, Inc. and Sapu Bioscience Expand International IP Coverage for OT-101, Strengthening CNS and Neurology Commercialization Pathway

Oncotelic Therapeutics, Inc. Showcases Multi-Year Execution and Validation, Enters 2026 with Late-Stage Momentum Across Diversified Pipeline

Oncotelic Therapeutics Details PDAOAI Platform and Opens Access to Its Total TGF-β Knowledge Corpus

Oncotelic Therapeutics and Brush and Key Foundation Announce Publication in International Journal of Molecular Sciences Highlighting Context-Dependent Biomarkers in Liver and Pancreatic Cancer

Oncotelic and Sapu Nano Announce DeciparticleTM Led Biomarker Framework Identifying Tumors Most Likely to Respond to IV Sapu003, an Intravenous Everolimus Nanomedicine

Oncotelic and Sapu Nano Announces New PK Data Demonstrating IV Sapu003 Reduces GI Accumulation of Everolimus up to 67-Fold Compared With Oral Dosing

Oncotelic and Sapu Nano Unveils Broad-Applicability Deciparticle™ Nanomedicine Platform Capable of Formulating Multiple Hydrophobic Peptide, Macrolide, and Polyketide Drugs

Oncotelic Therapeutics Inc. (OTCQB: OTLC) Anticipates Major Fair-Value Uptick Following New Independent JV Valuation

Oncotelic Therapeutics Inc. (OTCQB: OTLC) Emerging as Leader with New Independent JV Valuation

Oncotelic Achieves Breakthrough $1.7 Billion Pipeline Valuation Through GMP Bio Joint Venture

Oncotelic Therapeutics and Sapu Bioscience Announce Publication on Sub-15 nm Nanoparticles in International Journal of Molecular Sciences

Oncotelic Therapeutics Inc. (OTCQB: OTLC) at Forefront of Effort to Optimize Next-Generation Cancer Therapies

Sapu Nano to present at the 2025 San Antonio Breast Cancer Symposium (SABCS) Highlighting Sapu003 (Deciparticle™ Everolimus)

Oncotelic Therapeutics Inc. (OTCQB: OTLC) Working to Transform Underperforming Compounds into Next-Gen Cancer Therapies

Oncotelic to present at the 2025 San Antonio Breast Cancer Symposium (SABCS) Highlighting Sapu003 (Deciparticle™ Everolimus)

Oncotelic to Present at the LD Micro Main Event XIX

Sapu Nano Unveils First-in-Human Clinical Trial of Sapu-003 at 8th Australian Translational Breast Cancer Research Symposium

Sapu Nano's Sapu003 Advances to Human Clinical Testing - Transforming Everolimus Delivery with Full Bioavailability for Breast Cancer Patients

Oncotelic Therapeutics Inc. (OTCQB: OTLC) Creating Pioneering Pipeline Designed to Transform Cancer, Rare Diseases Treatments

Oncotelic Therapeutics Inc. (OTCQB: OTLC) Building Breakthrough Portfolio Aimed at Transforming Cancer, Rare Disease Treatments

Oncotelic Therapeutics Highlights 2 Years of Clinical and Regulatory Advancements Across Late-Stage Pipeline

Dr. Vuong Trieu, Developer of Novel Oncology and Immunotherapy Assets, Leads Oncotelic Therapeutics' Commitment to Innovation, Life-Saving Therapies

Oncotelic Therapeutics Showcases Robust Pipeline and Founder's Broad Intellectual Property Contributions to Biopharma Industry

Oncotelic Therapeutics Highlights Peer Reviewed Publication Linking TGFB2 to Survival in Younger Pancreatic Cancer Patients

Oncotelic Therapeutics Announces Publication of Landmark Study on TGFB2 Gene Methylation as a Positive Prognostic Marker in Pancreatic Cancer

Oncotelic CEO Vuong Trieu to Present Innovative "Deciparticles" Platform at IDDST-Europe 2025 Conference in Stockholm

Oncotelic Therapeutics Reports FY 2024 Highlights and FY 2024 Earnings Compared to FY 2023

Oncotelic Therapeutics Publishes New Research Demonstrating Positive Prognostic Impact of Methylated TGFB2 and MGMT in Adult Glioblastoma Patients, Introduces Interactive PDAOAI

Oncotelic Therapeutics Announces Successful Completion of Phase 1 Trial of OT-101 and IL-2, Highlights Findings at SWCR 2025 Conference

Oncotelic Accesses Rapid IND Development Platform through Partnership with Medicilon

Oncotelic CEO Vuong Trieu to Present Groundbreaking Research on Transforming Growth Factor Beta 2 (TGFB2) at SWCR 2025 Conference